Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Grepafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 3/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Grepafloxacin SCHEMBL29695614 | 1.00 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL34155 | 1.00 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL34156 | 1.00 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL29419670 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL2636690 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL1230941 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL7763531 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL7763536 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL137804 | 0.99 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| SCHEMBL9501145 | 0.93 | KCNH2 (0.87) | KCNH2HRH3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11967 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1017402-A1 | CONTROL OF ACIDIC GUT SYNDROME | UNIVERSITY OF NEW ENGLAND (AU) | 2000-07-12 | — | — | EP | claimed |
| WO-2000032196-A2 | INHIBITORS OF MULTIDRUG TRANSPORTERS | INFLUX, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| WO-2000025756-A2 | MEDICAMENT FOR TOPICAL TREATMENT OF INFLAMMATORY INTESTINAL DISEASES | DR. FALK PHARMA GMBH (DE) | 2000-05-11 | — | — | WO | claimed |
| WO-2000018404-A1 | ANTIBIOTIC COMPOSITIONS FOR TREATMENT OF THE EYE, EAR AND NOSE | ALCON LABORATORIES, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000012048-A2 | CARBAPENEM ANTIBACTERIAL COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-2000006122-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED TASTE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-10 | — | — | WO | claimed |
| WO-1999000136-A1 | CONTROL OF ACIDIC GUT SYNDROME | THE UNIVERSITY OF NEW ENGLAND (AU) | 1999-01-07 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |